Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in vivo experiments

Chinese Medicine

Research

Shan Lu¹  Zhishan Wu¹  Fanqin Zhang¹  Pengyun Liu¹  Jiarui Wu¹  Haojia Wang¹  Yingli Zhu¹  Chao Wu¹  Jiaqi Huang¹  Libo Geng²  Antony Stalin³  Huiying Li⁴  Xiaotian Fan⁵  Leiming You⁶ 

[1] Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, 100102, Beijing, China;Guizhou Yibai Pharmaceutical Co. Ltd, 550008, Guiyang, Guizhou, China;Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, 610054, Chengdu, China;School of Biology, Beijing Forestry University, 100091, Beijing, China;School of Chinese Medicine, Bozhou University, 236800, Bozhou, China;School of Life Sciences, Beijing University of Chinese Medicine, 100102, Beijing, China;

关键词: Pancreatic cancer;    Aidi injection;    Network pharmacology;    Molecular docking;    Pharmacodynamic evaluation;   

DOI  :  10.1186/s13020-023-00710-2

 received in 2022-10-31, accepted in 2023-01-08,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPancreatic cancer is one of the most lethal cancers worldwide. Aidi injection (ADI) is a representative antitumor medication based on Chinese herbal injection, but its antitumor mechanisms are still poorly understood.Materials and methodsIn this work, the subcutaneous xenograft model of human pancreatic cancer cell line Panc-1 was established in nude mice to investigate the anticancer effect of ADI in vivo. We then determined the components of ADI using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS) and explored the possible molecular mechanisms against pancreatic cancer using network pharmacology.ResultsIn vivo experiments, the volume, weight, and degree of histological abnormalities of implanted tumors were significantly lower in the medium and high concentration ADI injection groups than in the control group. Network pharmacology analysis identified four active components of ADI and seven key targets, TNF, VEGFA, HSP90AA1, MAPK14, CASP3, P53 and JUN. Molecular docking also revealed high affinity between the active components and the target proteins, including Astragaloside IV to P53 and VEGFA, Ginsenoside Rb1 to CASP3 and Formononetin to JUN.ConclusionADI could reduce the growth rate of tumor tissue and alleviate the structural abnormalities in tumor tissue. ADI is predicted to act on VEGFA, P53, CASP3, and JUN in ADI-mediated treatment of pancreatic cancer.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq387.gif

41116_2022_35_Article_IEq386.gif

Fig. 2

Fig. 4

41116_2022_35_Article_IEq366.gif

41116_2022_35_Article_IEq346.gif

41116_2022_35_Article_IEq337.gif

41116_2022_35_Article_IEq319.gif

41116_2022_35_Article_IEq315.gif

Fig. 2